http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
비스테로이드소염제를 투약하는 환자에서 소화성궤양의 예방
추성준 ( Seong Jun Chu ),윤규태 ( Kyu-tae Yoon ),김준성 ( Joon Sung Kim ) 대한소화기학회 2020 대한소화기학회지 Vol.76 No.5
Nonsteroidal anti-inflammatory drugs (NSAID) are some of the most commonly prescribed medications in clinical practice. The long-term use of NSAIDs is one of the main causes of peptic ulcers and the increased risk of upper gastrointestinal tract complications, such as perforation and bleeding. Thus, the prevention of NSAID-induced peptic ulcers is an important clinical issue. Previous studies have evaluated various strategies for preventing ulcers in patients requiring prolonged NSAID use. The Korean clinical practice guidelines have been published recently based on the evidence of the currently available data. This review describes the strategies for the prevention of peptic ulcers due to NSAID. An assessment of the risk factors for peptic ulcers from NSAID is recommended to identify patients who should be considered for primary prophylaxis. The risk of NSAID-induced peptic ulcers can be reduced by the concomitant use of proton pump inhibitors (PPI), misoprostol, and histamine-2 receptor antagonists. Selective cyclooxygenase-2 inhibitors can be used with caution due to concerns regarding cardiovascular toxicity. Attempts should be made to use the lowest dose and shortest duration of the NSAID. (Korean J Gastroenterol 2020;76:232-237)
P-83 Anticancer effects of Imipramine, repositioned drug, for Small Cell Lung Cancer
김기업,장준용,추성준,구소미,김양기,어수택 대한결핵 및 호흡기학회 2016 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.121 No.-
Introduction: Drug reposition is one of the blue oceans on discovery of new drugs. Anticancer new drugs by reposition are also vigorous mining area by in vivo, in vitro and in silico. Treatment of small cell lung cancer (SCLC) is restricted due to lack of chemotherapeutic agents. Imipramine, a challenging drug for SCLC was discovered by in silico reposition recently. We tried imipramine to the patients who diagnosed SCLC after 1st line chemotherapy. Method: From July of 2013 to December of 2015, patients who diagnosed SCLC were enrolled. All of them were treated 1st line combination chemotherapy, platinum and etoposide and some of them were done radiotherapy to main lesion. After chemotherapy or combined radiation therapy, imipramine was prescribed 25-75mg according to patient`s tolerance alternately. Results: Fifteen patients were participated, 6 (40%) of them were limited, 9 (60%) of them were extensive stage, but more limited stage in imipramine group compare to not prescribed group (4 to 2). All of them were smokers, 12 were man (80%), mean age was 64.6. Classified by TNM stage, stage 3 was 8, stage 4 was 7. There were no differences of age, performance status, cancer stage, chemotherapy and radiation. Amount and duration of imipramine, the prescribed group, was mean 55 mg, and 9 month. Survival of two groups was imipramine prescribed group, 22 ± 6.3 month, and not prescribed group 13.0 ± 2.8 month. (P=0.105) Conclusion: Trial of imipramine is one of the promising agent to control or maintenance of neuroendocrine tumor, especially SCLC.